Charles P. Andrews, MD

Dr
Diagnostics Research Group, San Antonio, TX, United States

Disclosure: GSK group of companies (Individual(s) Involved: Self): Scientific Research Study Investigator

Presentation(s):

• 119 - A Respiratory Syncytial Virus Prefusion F Protein (RSVPreF3) Candidate Vaccine Administered in Older Adults in a Phase I/II Randomized Clinical Trial Is Well Tolerated

  Oral Abstract

• 121 - A Respiratory Syncytial Virus Prefusion F Protein (RSVPreF3) Candidate Vaccine Administered in Older Adults in a Phase I/II Randomized Clinical Trial Is Immunogenic

  Oral Abstract